FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
top of page
Browse by category
Search
Endo Tools Therapeutics announces recruitment of first patient in ESTIME clinical trial
The first patient has been enrolled in Endo Tools Therapeutics’ (ETT) ESTIME clinical trial. The trial is evaluating ETT’s endomina...
Biolexis Therapeutics launches Metabolexis to develop novel oral medicines for obesity and T2DM
Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, has launched Metabolexis, a new pipeline company developing...
Viking Therapeutics completes of enrolment in VENTURE Trial for GLP-1/GIP receptor agonist VK2735
Viking Therapeutics has completed patient enrolment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of...
GE HealthCare and Novo Nordisk to collaborate on peripheral focused ultrasound for T2DM and obesity
GE HealthCare and Novo Nordisk are collaborating to further advance the clinical and product development of peripheral focused ultrasound...
First commercial use of Levita Magnetics’ MARS Surgical System
Levita Magnetics has announced the world's first commercial use of its MARS platform. The first commercial use, which took place in...
FDA clears GE HealthCare’s Allia IGS Pulse next generation of image-guided systems
GE HealthCare has gained FDA 510(k) clearance of the Allia IGS Pulse - the latest addition to the company’s image guided system (IGS)...
Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Allurion completes AUDACITY trial enrolment for Allurion Balloon
Allurion Technologies has completed patient enrolment in its AUDACITY trial, a randomised, pivotal controlled trial designed to support...
Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia begins
The first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
Browse by tag
bottom of page